Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;33(2):e13215.
doi: 10.1111/dth.13215. Epub 2020 Jan 12.

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Komal Agarwal  1 , Indrashis Podder  2 , Martin Kassir  3 , Aleksandra Vojvodic  4 , Robert A Schwartz  5 , Uwe Wollina  6 , Yan Valle  7 , Torello Lotti  8 , Ghasem R Rokni  9 , Stephan Grabbe  10 , Mohamad Goldust  11   12   13
Affiliations
Review

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Komal Agarwal et al. Dermatol Ther. 2020 Mar.

Abstract

Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as "vitiligo," "treatment," "recent," and "immunomodulators" to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.

Keywords: immunomodulators; new treatment; vitiligo.

PubMed Disclaimer

References

REFERENCES

    1. Abdelmaksoud, A., Dave, D. D., Lotti, T., & Vestita, M. (2019). Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature. Dermatologic Therapy, 32(5), e13013. https://doi.org/10.1111/dth.13013
    1. Agarwal, P., Rashighi, M., Essien, K. I., Richmond, J. M., Randall, L., Pazoki-Toroudi, H., … Harris, J. E. (2015). Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo. Journal of Investigative Dermatology, 135(4), 1080-1088. https://doi.org/10.1038/jid.2014.529
    1. AlGhamdi, K., Kumar, A., & Moussa, N. (2013). The role of vitamin D in melanogenesis with an emphasis on vitiligo. Indian Journal of Dermatology, Venereology, and Leprology, 79(6), 750. https://doi.org/10.4103/0378-6323.120720
    1. AlGhamdi, K. M., Khurrum, H., Taieb, A., & Ezzedine, K. (2012). Treatment of generalized vitiligo with anti-TNF-a agents. Journal of Drugs in Dermatology, 11(4), 534-539.
    1. Anbar, T. S., El-Ammawi, T. S., Abdel-Rahman, A. T., & Hanna, M. R. (2015). The effect of latanoprost on vitiligo: A preliminary comparative study. International Journal of Dermatology, 54(5), 587-593. https://doi.org/10.1111/ijd.12631

Substances